# OnCo record nct06672068 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06672068/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06672068", "NCT06672068" ;
  schema:name "A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC"@en ;
  schema:description "A phase 2 trial of pemetrexed, cisplatin and carboplatin in lung cancer, run by TYK Medicines, Inc, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06672068/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06672068> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/> .